Trial Profile
Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.
- 16 Dec 2022 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.
- 16 Dec 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2023.